Centre for Human Drug Research’s Post

🎉 A Breakthrough in Treating Deadly Skin Disease: World-First Cure Achieved! In an incredible leap forward for medical science, researchers have successfully cured patients suffering from Toxic Epidermal Necrolysis (TEN), a rare and often fatal skin condition, through an innovative use of existing drugs. Published in Nature, this landmark study could pave the way for an approved curative therapy, offering hope where there was previously very little. 🔬 Study Highlights: ◾ TEN, characterized by severe skin blistering and a high mortality rate, was halted using JAK inhibitors, drugs already used for inflammatory diseases. ◾ The study not only saved lives but also opened new doors in the treatment of other severe skin disorders and inflammatory conditions. 🌍 Global Impact: This pioneering work represents a monumental step in dermatology and emergency medicine, showcasing the power of collaborative research and the repurposing of drugs to fast-track life-saving treatments. 🔗 https://lnkd.in/grttG9-Q #MedicalResearch #Dermatology #HealthcareInnovation #SkinDisease #LifeSavingResearch

PELOPaperAlert: Advanced Skin Research with a Psoriasis Skin Equivalent Model A recent study published in Communications Biology, a Nature Portfolio journal, by Bianka Morgner, Dr. rer. nat., Oliver Werz, Cornelia Wiegand and Jörg Tittelbach introduces a bilayered skin equivalent that closely mimics psoriasis. This innovative model is a valuable predictive tool for preclinical treatment studies, offering critical insights into disease mechanisms and therapeutic interventions. Key Findings: ✔️ Successful Developing a bi-layered skin equivalent replicating key psoriasis features enables precise preclinical testing. ✔️ Enhanced understanding of cellular responses to therapeutic agents within a controlled in vitro environment. Products used from PELOBiotech: Primary Dermal Fibroblasts: Essential for constructing robust skin models with physiological relevance. Insulin: Supporting optimized cellular differentiation and enhanced functionality. These products were critical in achieving the study's outcomes and ensuring reliable and reproducible experimental results. 📖 Read the full study here: https://lnkd.in/drch5GE4 or a short version on our website: https://lnkd.in/dSMDW29B #SkinResearch #PsoriasisModel #PELOBiotech #fibroblasts #PrimaryCells #NatureCommunicationsBiology #PreclinicalStudies #Dermatology

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

Webcast Alert! Chronic Spontaneous Urticaria: A Targeted Approach. Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both; it may be considered chronic if the symptoms persist for more than 6 weeks. In some patients, chronic urticaria will be spontaneous, meaning that triggers (whether known or unknown) inconsistently cause symptoms. Though relatively rare, chronic spontaneous urticaria (CSU) can be a debilitating, difficult-to-treat condition, hugely impacting patients’ quality of life in all domains. In order to direct patients with CSU to effective management regimens, clinicians first need to be confident in their ability to diagnose CSU. In this webcast, Brian S. Kim, MD, describes the pathophysiology of CSU, before delving into case examples and clinical trial evidence that support strategies for CSU management. Click here to start the webcast: https://bit.ly/3zCsHNV #Webcast #NACE #Dermatology

Productive week in Germany and Basel Switzerland! Big movements in Digital Health Technology for Oncology , CRS detection for CAR-T and BiTE Therapies, lets connect on our CRS Consortium , the pathway to community clinics. Also the rumors are true!!! Biofourmis is moving the needle in collaborations with our clinically validated Nocturnal Scratch and Sleep Algorithm partnership for Atopic Dermatitis. Our agnostic (algorithm, device and therapeutic) platform has the ability to measure quantitatively, passively and in an unbiased manner nocturnal scratching (# of events and duration) and sleep quantity to provide endpoints with high accuracy, specificity and sensitivity in patients from 2- 75 years of age. We give you the ability to assess AD symptomatology, burden and response to treatments all in one place. #DCT, #DCTstrategies, #DecentralizedClinicalTrials #DHT #ClinicalTrials #Regulatory #Validation #CART, #BiTE #Immunotherapy,#oncology #AtopicDermatitis #Dermatology #Psoriais #Eczema

Identify Biologic-Eligible Patients, Hurley Stage 2 or 3, in Hidradenitis Suppurativa (HS) Patients Challenge:  ✅Understanding the specific patient characteristics that show which HS patients are likely to respond to biologic therapy. Data pulled from OM1’s PremiOM HS Dataset: ✅About 24,500 HS patients with clinical notes ✅93% of HS patients in the OM1 RWDC have linked EMR and medical claims data Solution:  ✅Leverage OM1 linked, clinical EMR and claims data that includes Hurley stage, Estimated Hurley Stage, disease manifestation (i.e. cyst, nodule, abscess),  steroid dosing and exposure. OM1 data also includes extracted disease activity descriptors for body location and use of bDMARDs. If you're interested in how we can help take your HS research to the next level, or exploring your own potential use cases, you can find more details here; 📍 OM1's HS RWD; https://lnkd.in/easUxw77 📍Book a Meeting with us; https://lnkd.in/eJcKBAJK #hidradenitissuppurativa #HS #researchanddevelopment #RWD #Dermatology #ClinicalTrials

I'm excited to announce that I will be participating as a speaker in an upcoming online webinar titled "Different Modes of Action in Atopic Dermatitis" on July 31, 2024, from 20:00 to 21:00. I will be presenting "Unraveling the Pathomechanisms of Atopic Dermatitis: Insights and Innovations," where I'll delve into the latest research and advancements in understanding and treating this complex condition. Joining me is Professor Alon Hershko, who will discuss "The Atopic March – Different Diseases with a Common Mechanism." Together, we aim to provide a comprehensive overview of atopic dermatitis and related conditions. The event will conclude with a panel discussion, allowing for an interactive and engaging session with our audience. For more details and registration, please refer to the following link: https://lnkd.in/dqUJAY6t. Looking forward to a productive session and hoping to see many of you there! #Dermatology #AtopicDermatitis #Webinar #MedicalEducation #Research

EI Cure Project is pleased to announce our support for a 1-year research project led by Dr Leonie Frommherz and Professor Cristina Has: “Influence of inflammation parameters and signalling cascades for potential therapeutic approaches in Epidermolytic Ichthyosis: a comprehensive analysis integrating proteomic and RNA-Sequence data”. These two wonderful dermatology scientists were key members of the team who recently published the largest population study of EI ever seen: https://lnkd.in/e47a6eBF This new research project aims to build on this work and stands to become the largest evaluation of biological data on EI. Whilst the EI Cure Project is committed to finding a gene-editing solution to cure EI, we also recognise that the EI Community needs better options to relieve symptoms NOW! The aim of this new project is to understand those symptoms better by exploring diagnostic bio markers, and to hopefully identify some new therapeutic targets for drug repurposing. We are excited that this project could lead us to new solutions within the immediate future. Thank you so much Leonie and Cristina, it’s so great to have you in our corner! 🥰 #eicureproject #hope4ei #drugrepurposing #proteomics #RNAsequencedata #epidermolyticichthyosis #ichthyosisawareness #ichthyosisresearch #RAREderm #dermatology

Our Head of Clinical Operations, Leonie Middelink, and Scientist, Stephanie van Dalen, are looking forward to attending the 9th Annual Symposium on Hidradenitis Suppurativa Advances, taking place in Austin, Texas, from 1-3 November. During the conference Stephanie will share a poster on Citryll’s latest research in Hidradenitis Suppurativa (HS), titled "Neutrophil Extracellular Traps in HS skin and serum as a target for CIT-013, a NET targeting therapy". Be sure to check out our poster and discover how Citryll is revolutionizing the world of immune-mediated inflammatory diseases! Learn more about SHSA: https://lnkd.in/gBZZwg4f #SHSA2024 #Dermatology #NETosis #Citryll #ClinicalResearch

💡Psoriasis Treatment is Evolving! 💡 Spherix Global Insights highlights the excitement around pipeline agents like Johnson & Johnson’s oral IL-23 asset, JNJ-2113, which reflects high expectations for it to capture significant market share, potentially outpacing other oral candidates and shifting the timelines for initiating biologic treatments. Competing with JNJ-2113 in the pipeline are several promising TYK2 inhibitors, including ESK-001 from Alumis, zasocitinib (TAK-279) from Takeda, and BMS-986322 from Bristol Myers Squibb. With patient preference shifting towards oral options, these innovative treatments could reshape the market and improve care. Read more: https://lnkd.in/e4JfAKMy #Psoriasis #Dermatology #EmergingTherapies #MarketResearch